Supplementary Table 1. Proportion of participants with inflammatory bowel disease or immunocompromise by presence of severe baseline disease or recurrence

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | Inflammatory bowel disease n (%) | |  | Immunocompromiseda  n (%) | |  |
|  | Yes | No |  | Yes | No |  |
| Severe baseline disease |  |  | *P* value |  |  | *P* value |
| Yes | 1  (7.1%) | 33  (23.2%) | 0.31 | 9  (11.0%) | 25  (33.8%) | <0.001 |
| No | 13  (92.9%) | 109  (76.8%) | 73  (89.0%) | 49  (66.2%) |
| Recurrence |  |  |  |  |  |  |
| Yes | 2  (8.7%) | 15  (9.2%) | 1.00 | 9  (10.2%) | 8  (8.1%) | 0.62 |
| No | 21  (91.3%) | 149  (90.9%) | 79  (89.8%) | 91  (91.9%) |

aImmunocompromised defined as any of the following at the time of diagnosis of *C. difficile* infection: malignancy with receipt of active chemotherapy, hematopoietic stem cell transplant recipient on immunosuppression or with graft vs. host disease, or history of solid organ transplantation